Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE)

Q: What does CUSIP 78667J108 represent in this 13F holders report?

CUSIP 78667J108 is the security identifier for SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") used to aggregate holder disclosures.

Q: How many institutions held SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") in Q1 2016?

138 institutional investors reported SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") for Q1 2016. Use the holders table for investor-level position and value details.

CUSIP: 78667J108

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class: Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
Shares outstanding: 62,650,155
Total 13F shares: 29,073,553
Share change: +5,818,251
Total reported value: $931,907,546
Put/Call ratio: 79%
Price per share: $32.06
Number of holders: 138
Value change: +$174,147,459
Number of buys: 95
Number of sells: 43

Quarterly Holders Quick Answers

What is CUSIP 78667J108?
CUSIP 78667J108 identifies SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2016
Previous quarter: Q4 2015

Recent filing periods for CUSIP 78667J108:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	6.9%	4,328,270	$252,338,000	—	31 Dec 2015	13F
VANGUARD GROUP INC	13F	Company	2.1%	1,331,977	$77,654,000	—	31 Dec 2015	13F
FRANKLIN RESOURCES INC	13F	Company	1.9%	1,194,331	$69,630,000	—	31 Dec 2015	13F
LORD, ABBETT & CO. LLC	13F	Company	1.7%	1,095,283	$63,855,000	—	31 Dec 2015	13F
Visium Asset Management, LP	13F	Company	1.7%	1,075,309	$62,690,000	—	31 Dec 2015	13F
JPMORGAN CHASE & CO	13F	Company	1.5%	966,408	$56,341,000	—	31 Dec 2015	13F
Redmile Group, LLC	13F	Company	1.5%	958,374	$55,873,000	—	31 Dec 2015	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	1.5%	917,882	$53,513,000	—	31 Dec 2015	13F
EAGLE ASSET MANAGEMENT INC	13F	Company	1.4%	864,370	$50,392,000	—	31 Dec 2015	13F
BB BIOTECH AG	13F	Company	1.1%	708,663	$41,315,000	—	31 Dec 2015	13F
BlackRock Fund Advisors	13F	Company	1.1%	672,519	$39,208,000	—	31 Dec 2015	13F
OAK RIDGE INVESTMENTS LLC	13F	Company	1%	651,420	$37,977,000	—	31 Dec 2015	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	0.96%	598,854	$34,913,000	—	31 Dec 2015	13F
STATE STREET CORP	13F	Company	0.85%	531,935	$31,011,000	—	31 Dec 2015	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.83%	518,738	$30,242,000	—	31 Dec 2015	13F
GILDER GAGNON HOWE & CO LLC	13F	Company	0.82%	512,080	$29,854,000	—	31 Dec 2015	13F
RS INVESTMENT MANAGEMENT CO LLC	13F	Company	0.81%	504,405	$29,407,000	—	31 Dec 2015	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.61%	381,525	$22,243,000	—	31 Dec 2015	13F
Cormorant Asset Management, LP	13F	Company	0.5%	315,000	$18,365,000	—	31 Dec 2015	13F
Bank of New York Mellon Corp	13F	Company	0.5%	310,827	$18,122,000	—	31 Dec 2015	13F
BlackRock Institutional Trust Company, N.A.	13F	Company	0.44%	277,513	$16,179,000	—	31 Dec 2015	13F
Granahan Investment Management, LLC	13F	Company	0.44%	274,885	$16,026,000	—	31 Dec 2015	13F
JENNISON ASSOCIATES LLC	13F	Company	0.41%	255,145	$14,875,000	—	31 Dec 2015	13F
CITADEL ADVISORS LLC	13F	Company	0.38%	239,673	$13,973,000	—	31 Dec 2015	13F
APEX CAPITAL, LLC	13F	Company	0.36%	225,000	$13,118,000	—	31 Dec 2015	13F
FEDERATED HERMES, INC.	13F	Company	0.33%	205,000	$11,952,000	—	31 Dec 2015	13F
Ghost Tree Capital, LLC	13F	Company	0.32%	200,000	$11,660,000	—	31 Dec 2015	13F
HIGHLAND CAPITAL MANAGEMENT LP	13F	Company	0.24%	152,985	$8,919,000	—	31 Dec 2015	13F
NORTHERN TRUST CORP	13F	Company	0.24%	151,685	$8,843,000	—	31 Dec 2015	13F
Casdin Capital, LLC	13F	Company	0.23%	143,011	$8,338,000	—	31 Dec 2015	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.2%	125,900	$7,340,000	—	31 Dec 2015	13F
NORGES BANK	13F	Company	0.19%	120,566	$7,029,000	—	31 Dec 2015	13F
BLACKROCK ADVISORS LLC	13F	Company	0.19%	118,389	$6,902,000	—	31 Dec 2015	13F
OXFORD ASSET MANAGEMENT LLP	13F	Company	0.19%	115,936	$6,751,000	—	31 Dec 2015	13F
BAKER BROS. ADVISORS LP	13F	Company	0.17%	105,000	$6,122,000	—	31 Dec 2015	13F
HARBOURVEST PARTNERS LLC	13F	Company	0.17%	104,568	$6,096,000	—	31 Dec 2015	13F
Opaleye Management Inc.	13F	Company	0.16%	100,000	$5,830,000	—	31 Dec 2015	13F
Tekla Capital Management LLC	13F	Company	0.16%	97,800	$5,702,000	—	31 Dec 2015	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.15%	93,000	$5,422,000	—	31 Dec 2015	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.15%	92,991	$5,422,000	—	31 Dec 2015	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.13%	80,650	$4,701,000	—	31 Dec 2015	13F
GAM Holding AG	13F	Company	0.13%	79,400	$4,629,000	—	31 Dec 2015	13F
AlpInvest Partners B.V.	13F	Company	0.13%	78,641	$4,585,000	—	31 Dec 2015	13F
S.c.a. Candriam	13F	Individual	0.12%	76,200	$4,442,000	—	31 Dec 2015	13F
GUGGENHEIM CAPITAL LLC	13F	Company	0.11%	69,160	$4,032,000	—	31 Dec 2015	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.1%	62,729	$3,657,000	—	31 Dec 2015	13F
Nicholas Investment Partners, LP	13F	Company	0.1%	61,789	$3,602,000	—	31 Dec 2015	13F
HERSHEY TRUST CO	13F	Company	0.09%	58,940	$3,436,000	—	31 Dec 2015	13F
LAZARD ASSET MANAGEMENT LLC	13F	Company	0.09%	57,300	$3,340,000	—	31 Dec 2015	13F
PICTON MAHONEY ASSET MANAGEMENT	13F	Company	0.09%	57,100	$3,329,000	—	31 Dec 2015	13F

Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q1 2016

As of 31 Mar 2016, Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by 138 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 29,073,553 shares. The largest 10 holders included FMR LLC, VANGUARD GROUP INC, Visium Asset Management, LP, FRANKLIN RESOURCES INC, DEERFIELD MANAGEMENT CO, Redmile Group, LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., Cormorant Asset Management, LLC, and EAGLE ASSET MANAGEMENT INC. This page lists 138 institutional shareholders reporting positions in this security for the Q1 2016 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2016 vs Q4 2015 Across Filers

Q4 2015 holders

135

Q1 2016 holders

138

Holder diff

Investor	Q4 2015 Shares	Q1 2016 Shares	Share Diff	Share Chg %	Q4 2015 Value $	Q1 2016 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.